Stevens–Johnson Syndrome and toxic epidermalnecrolysis: a multi-aspect comparative 7-year study from the People’s Republic of China
Authors Sun J, Liu J, Gong Q, Ding G, Ma L, Zhang L, Lu Y
Received 25 July 2014
Accepted for publication 27 August 2014
Published 12 December 2014 Volume 2014:8 Pages 2539—2547
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 4
Editor who approved publication: Professor Shu-Feng Zhou
Jie Sun,1 Jin Liu,2 Qing-Li Gong,1 Gao-Zhong Ding,1 Li-Wen Ma,1 Li-Chao Zhang,1 Yan Lu1
1Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, 2Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu Province, People’s Republic of China
Background: Stevens–Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but severe cutaneous drug reactions. They are differentiated based on the fraction of the body surface area affected. Optimal therapy for SJS and TEN is a controversial issue.
Objective: We compared the treatments given to and the clinical outcomes of 39 cases of SJS and 48 cases of TEN seen at a single institution between January 2007 and December 2013 for better understanding of the clinical characteristics and development of the two conditions.
Methods: Demographic data, clinical characteristics, treatments given, and therapeutic responses observed were retrospectively collected.
Results: The incidence rates of hypoproteinemia and secondary infections are significantly higher in TEN than in SJS (P=0.001 and P=0.002, respectively). The corticosteroid dose did not influence the time from the initiation of therapy to control of the lesions in SJS, but increasing the dosage of corticosteroids progressively decreased the time from the initiation of therapy to control of the lesions in TEN. With increases in the utilization ratio of intravenous immunoglobulin (IVIG), the length of the hospital stay became shorter, whereas the time from the initiation of therapy to control of the lesions remained the same in SJS. However, for TEN, both the length of the hospital stay and the time from the initiation of therapy to control of the lesions became shorter with increases in the utilization ratio of IVIG.
Conclusion: SJS and TEN are two variants of the same spectrum, and they differ from each other not only in the severity of epidermal detachment but also in other clinical parameters and their distinct clinical courses. Thus, differential treatment of both conditions may have benefits for their prognosis.
Keywords: corticosteroids, intravenous immunoglobulin, Stevens–Johnson Syndrome, toxic epidermal necrolysis, cutaneous drug reaction
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]